Ashland Cuts 2026 Outlook After Mixed Q2 Results

The latest update is out from Ashland ( (ASH) ).

Ashland reported second quarter fiscal 2026 results for the period ended March 31, 2026, with sales of $482 million, up 1 percent year over year, but net income falling to $16 million and adjusted EBITDA down 9 percent to $98 million. Performance was mixed across segments, with strong growth in Personal Care, resilient pharma-driven Life Sciences, stabilization in Specialty Additives and trough-level but stable Intermediates, while operational headwinds at the Hopewell facility, the Calvert City startup delay, weather disruptions and softer pricing weighed on profitability and prompted a reduction in full‑year 2026 sales and adjusted EBITDA guidance.

Management highlighted that operational issues at Hopewell are internal and controllable, noting product quality and customer service were maintained even as productivity lagged expectations. The company completed repairs at Calvert City, managed winter storm shutdowns and supply chain disruptions linked to Middle East tensions, and began implementing price increases to offset higher energy and logistics costs, while also delivering significantly stronger operating cash flow and positive free cash flow through tighter working capital and lower capital spending.

Within Life Sciences, sales were flat at $172 million as steady pharma growth in high-purity excipients, injectables and tablet coatings offset weakness in nutrition and other non‑pharma end markets, but segment margins compressed due to lower pricing, higher costs and the Calvert City impact. Adjusted EBITDA in Life Sciences fell to $50 million with a 29 percent margin, down 11 percent from the prior year, though management emphasized ongoing benefits from its “globalize and innovate” initiatives and the potential for improved value capture as pricing actions take hold and operating conditions normalize.

The most recent analyst rating on (ASH) stock is a Hold with a $60.00 price target. To see the full list of analyst forecasts on Ashland stock, see the ASH Stock Forecast page.

Spark’s Take on ASH Stock

According to Spark, TipRanks’ AI Analyst, ASH is a Neutral.

The score is held back primarily by the sharp TTM earnings deterioration and reported net loss, despite resilient cash generation. Offsetting factors include a generally positive intermediate technical trend, a modest dividend yield, and an earnings-call outlook that maintains EBITDA guidance and cost-savings plans while acknowledging near-term operational and demand headwinds.

To see Spark’s full report on ASH stock, click here.

More about Ashland

Ashland Inc., based in Wilmington, Del., is a global additives and specialty ingredients company with leadership positions in high-quality, consumer-focused markets. The company primarily serves pharmaceuticals, personal care and architectural coatings, with additional exposure to specialty additives and intermediates, emphasizing innovation, global expansion and resilient, high‑margin applications.

Average Trading Volume: 680,193

Technical Sentiment Signal: Sell

Current Market Cap: $2.63B

For an in-depth examination of ASH stock, go to TipRanks’ Overview page.